Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops vaccines.
Year Established: | |
Funding: | |
Address: | Seattle, WA 98104 |
Telephone: | 2066820645 |
Mobile: | |
Fax: | 206-682-0648 |
Mail: | info@immunedesign.com |
Company URL: | http://www.immunedesign.com |
Immune Design Corp. is a focused on using a world-class technology platform for the development of novel vaccines. We are committed to pursuing the highest quality science while building a strong pipeline of products that will treat infectious diseases world-wide. We are assembling an excellent team of experienced scientists and are looking for the very best and brightest people as we continue to grow. Please contact us if you are searching for a stimulating environment where discovery and development of vaccine-based therapies is a passion.
Equal employment opportunity is a fundamental principle at IDC. We are committed to a work environment that values dignity, courtesy and respect. Employment is based upon personal capabilities and qualifications without discrimination because of race, color, religion, sex, sexual orientation,age, national origin, disability, or any other protected class as established by law.
Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.
DRI (Infectious Disease Research Institute) and Immune Design Corp. announced today that they have entered into an agreement pursuant to which Immune Design Corp. is granted a worldwide exclusive license for the research, development, and commercialization of IDRI's Glycopyranosyl Lipid Adjuvant (GLA) technology for products targeting a number of indications. Focusing on its mission to fight infectious diseases of the developing world, IDRI retains worldwide exclusive rights to GLA for selected diseases affecting predominately the developing world. Under the agreement, IDRI will receive an upfront payment, milestones, and royalty payments as well as shares in Immune Design Corp. Further details on the financial terms were not disclosed. IDRI and Immune Design Corp. Enter License Agreement.
Vaccines are coming back in a big way. Immune Design, a Seattle-based startup vaccine company, made that clear today when it said it raised $18 million in an initial round of venture capital.
If you are a member of the media, please contact us regarding any potential news interest.
Alta Partners,Column Group, The,Versant Ventures